Recombinant Pelophylax ridibundus Brevinin-2Eg
Description
Recombinant Production
Recombinant Brevinin-2Eg is synthesized using Escherichia coli expression systems, following protocols similar to other Brevinin-2 peptides . Key production parameters include:
-
Expression Vector: Cytoplasmic domain constructs.
-
Purification: Ion exchange chromatography and ultrafiltration .
-
Storage: Lyophilized or in liquid form at -20°C to -80°C with glycerol stabilizers .
Antimicrobial Activity
Brevinin-2Eg demonstrates broad-spectrum antimicrobial efficacy, particularly against Gram-negative bacteria like Escherichia coli and Gram-positive Staphylococcus aureus.
Table 2: Antimicrobial Activity Profile6
| Pathogen | MIC (μM) | HC50 (Hemolytic Activity, μM) |
|---|---|---|
| Escherichia coli | 12.5 | >100 |
| Staphylococcus aureus | 25 | >100 |
Mechanistically, it disrupts microbial membranes and hydrolyzes genomic DNA . Its low hemolytic activity (HC50 >100 μM) makes it a promising candidate for therapeutic use .
Comparative Analysis with Brevinin-2 Family
Brevinin-2Eg shares functional similarities with other Brevinin-2 peptides but exhibits unique features:
-
Low Hemolysis: Unlike many Brevinin-2 peptides, Brevinin-2Eg has minimal hemolytic effects at antimicrobial concentrations .
-
Structural Variability: The C-terminal domain varies across species, influencing target specificity .
Research Applications
-
Antibacterial Drug Development: Its efficacy against multidrug-resistant bacteria (e.g., Acinetobacter baumannii) is under investigation .
-
Wound Healing: Related Brevinin-2 peptides (e.g., Brevinin-2PN) accelerate fibroblast migration and growth factor expression, suggesting similar potential for Brevinin-2Eg .
-
Nanoparticle Conjugation: Brevinin peptides are being tested for targeted drug delivery systems .
